Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 25
1979 37
1980 35
1981 27
1982 28
1983 54
1984 38
1985 45
1986 63
1987 73
1988 44
1989 73
1990 84
1991 79
1992 110
1993 103
1994 121
1995 108
1996 124
1997 119
1998 139
1999 102
2000 113
2001 78
2002 85
2003 93
2004 78
2005 86
2006 98
2007 77
2008 59
2009 52
2010 61
2011 54
2012 59
2013 57
2014 41
2015 54
2016 60
2017 60
2018 55
2019 38
2020 39
2021 42
2022 50
2023 45
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

3,038 results

Results by year

Filters applied: . Clear all
Page 1
The pharmacology of selegiline.
Magyar K. Magyar K. Int Rev Neurobiol. 2011;100:65-84. doi: 10.1016/B978-0-12-386467-3.00004-2. Int Rev Neurobiol. 2011. PMID: 21971003 Review.
The metabolites are also taking part in the complex pharmacological activity of selegiline. The simultaneous presence of the pro- and antiapoptotic effects of selegiline and its metabolites frequently hindered its clinical usage. ...Selegiline is administered …
The metabolites are also taking part in the complex pharmacological activity of selegiline. The simultaneous presence of the pro- and …
Rasagiline.
Schapira A, Bate G, Kirkpatrick P. Schapira A, et al. Nat Rev Drug Discov. 2005 Aug;4(8):625-6. doi: 10.1038/nrd1803. Nat Rev Drug Discov. 2005. PMID: 16106586 No abstract available.
Metabolism of selegiline [(-)-deprenyl)].
Kalász H, Magyar K, Szőke É, Adeghate E, Adem A, Hasan MY, Nurulain SM, Tekes K. Kalász H, et al. Curr Med Chem. 2014;21(13):1522-30. doi: 10.2174/0929867321666131218094352. Curr Med Chem. 2014. PMID: 24350849 Review.
Selegiline (1) [(-)-deprenyl] is used to treat patients with Parkinson's disease. ...In addition, more than 40 minor metabolites of selegiline (1) have also been either detected or proposed by investigators and researchers. ...
Selegiline (1) [(-)-deprenyl] is used to treat patients with Parkinson's disease. ...In addition, more than 40 minor metabolites of
Pharmacology of selegiline.
Gerlach M, Youdim MB, Riederer P. Gerlach M, et al. Neurology. 1996 Dec;47(6 Suppl 3):S137-45. doi: 10.1212/wnl.47.6_suppl_3.137s. Neurology. 1996. PMID: 8959982 Review.
Selegiline is readily absorbed from the gastrointestinal tract and rapidly enters the brain and spinal cord following oral administration. ...Therefore, there is no clear knowledge regarding an understanding of the reported effects of selegiline on the progression o
Selegiline is readily absorbed from the gastrointestinal tract and rapidly enters the brain and spinal cord following oral administra
Selegiline: a molecule with innovative potential.
Tábi T, Vécsei L, Youdim MB, Riederer P, Szökő É. Tábi T, et al. J Neural Transm (Vienna). 2020 May;127(5):831-842. doi: 10.1007/s00702-019-02082-0. Epub 2019 Sep 27. J Neural Transm (Vienna). 2020. PMID: 31562557 Free PMC article. Review.
The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magyar and the original idea of Riederer and Youdim, supported by Birkmayer, to explore its effect in parkinsonian patients with on-off phases. . …
The first was the elucidation of the novel pharmacological properties of selegiline as a selective MAO-B inhibitor by Knoll and Magya …
Neuroprotective actions of selegiline.
Ebadi M, Sharma S, Shavali S, El Refaey H. Ebadi M, et al. J Neurosci Res. 2002 Feb 1;67(3):285-9. doi: 10.1002/jnr.10148. J Neurosci Res. 2002. PMID: 11813232 Review.
Selegiline, a selective inhibitor of monoamine oxidase-B (MAO-B), was one of the first adjunct therapies in clinical neurology. ...Most of the aforementioned properties occur independently of selegiline's efficacy to inhibit MAO-B....
Selegiline, a selective inhibitor of monoamine oxidase-B (MAO-B), was one of the first adjunct therapies in clinical neurology. ...Mo
Selegiline-transdermal--Somerset: Emsam.
[No authors listed] [No authors listed] Drugs R D. 2003;4(1):59-60. doi: 10.2165/00126839-200304010-00012. Drugs R D. 2003. PMID: 12568641 Review. No abstract available.
Selegiline.
Landau WM. Landau WM. Neurology. 1993 Dec;43(12):2728. doi: 10.1212/wnl.43.12.2728. Neurology. 1993. PMID: 8255493 No abstract available.
Transdermal selegiline.
Patkar AA, Pae CU, Zarzar M. Patkar AA, et al. Drugs Today (Barc). 2007 Jun;43(6):361-77. doi: 10.1358/dot.2006.43.6.1050794. Drugs Today (Barc). 2007. PMID: 17612708 Review.
Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called selegiline transdermal system (STS). STS has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of major depression. Transder …
Efforts to address these safety issues led to the development of a transdermal formulation of selegiline, called selegiline tr …
Selegiline ameliorated dyslipidemia and hepatic steatosis in high-fat diet mice.
Tian Z, Wang X, Han T, Sun C. Tian Z, et al. Int Immunopharmacol. 2023 Apr;117:109901. doi: 10.1016/j.intimp.2023.109901. Epub 2023 Feb 21. Int Immunopharmacol. 2023. PMID: 36822098
This study aimed to investigate the effects of a selective MAO-B inhibitor, selegiline, on dyslipidemia and hepatic steatosis in mice induced by a high-fat diet (HFD). ...Furthermore, selegiline dramatically reduced the total triglyceride (TG) and cholesterol (TC) l …
This study aimed to investigate the effects of a selective MAO-B inhibitor, selegiline, on dyslipidemia and hepatic steatosis in mice …
3,038 results